Acute cardiac care & resuscitationRandomised controlled trial
Early Intra-Aortic Balloon Support for Heart Failure-Related Cardiogenic Shock
- Randomised controlled trial
- multicentre
- prospective
- prespecified interim analysis
Authors' conclusion
Routine early IABP plus standard care, compared with standard care, did not significantly improve survival or successful bridging to HRT in patients with HF-CS.
Study context
- Population
- Patients with SCAI stage B, C or D HF-related cardiogenic shock suitable for heart replacement therapies
- Participants
- 53 vs 48
- Comparison
- Early IABP plus standard care vs standard care
- IABPn = 53
- Controln = 48reference
- Primary endpoint
- Survival or successful bridge to heart replacement therapy
- Follow-up
- 60 days
Primary result
As reported in the abstract
Hazard ratio
0.72
95% CI 0.31–1.68
P = 0.45
Events by treatment group
IABP vs Control
HR 0.72 (95% CI 0.31–1.68); P = 0.45
Secondary outcomes
Escalation
| Outcome | IABP | Control |
|---|---|---|
| Crossover from standard care to IABP | Not reported in the abstract | 13% |
Heart replacement therapy within 60 days (overall)
- Patients who underwent heart replacement therapies (HRT)
- 37 (37%)
Safety
Complications
- Complications comparable between groups
Original publication
Early Intra-Aortic Balloon Support for Heart Failure-Related Cardiogenic Shock. J Am Coll Cardiol. Published 30 March 2025. doi:10.1016/j.jacc.2025.03.003
Summarised from the published abstract; every number is checked against it